Moreover, since our previous investigations on human RNASET2 protein unveiled its ability to modulate in vivo the recruitment of myeloid cells in the TME (in particular by triggering M1-polarized macrophages recruitment in in vivo xenograft-based murine models of human cancer) [1,2], the development of our syngeneic mouse model allowed us to further investigate the relationship of macrophages and other immune cells involved in the anti-tumor immune response. This evidence concerns the gene RNASET2 and cancer.